UT Southwestern-linked CNS disease drug developer Taysha has filed to raise up to $100m in an IPO, just weeks after its $96m series B.

Taysha Gene Therapies, a US-based gene therapy developer based on research at University of Texas (UT) Southwestern, filed for a $100m initial public offering on Wednesday. Founded in 2019 in partnership with UT Southwestern Medical Center, and launched in April this year, Taysha is developing gene therapies for monogenic diseases of the central nervous system…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.